Drugs / 13-deoxydoxorubicin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00003403 | Aug 1999 → ? | cancer of unknown primary site | Gem Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00123877 | Mar → Nov 2005 | breast cancer, metastatic neoplasm | Gem Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-deoxydoxorubicin | “GPX-100 (13-deoxydoxorubicin)” NCT00123877 ↗ |
| Known as | GPX-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00123877 ↗ |
| Modality | Small molecule | — CHEMBL3249110 ↗ |
| Route | Intravenous | “Patients receive GPX-100 IV once every 3 weeks.” NCT00003403 ↗ |